A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer
A Phase 2, Open Label, Single Arm Trial of TPI 287 in Patients With Advanced, Unresectable Pancreatic Cancer After Prior Treatment With a Gemcitabine-based Therapy
Sponsor: Cortice Biosciences, Inc.
Terminated
Insufficient funding
Other terminated trials from Cortice Biosciences, Inc.
- Brain Lesions · Phase PHASE1 · Mar 2018
- Melanoma · Phase PHASE1 · Jul 2016
- Brain Neoplasms · Phase PHASE1/PHASE2 · Mar 2016
- Glioblastoma Multiforme · Phase PHASE2 · Dec 2015
- Medulloblastoma · Phase PHASE1/PHASE2 · Dec 2014
More terminations from Cortice Biosciences, Inc.
A PHASE2 clinical study on Pancreatic Cancer, this trial is terminated or withdrawn. The trial is conducted by Cortice Biosciences, Inc. and has accumulated 8 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Oct 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cortice Biosciences, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .